Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas.
The treatment of malignant gliomas has advanced significantly in the past 15 years. The simultaneous development of new targeting agents and techniques to deliver these high-molecular-weight compounds has led to improved efficacy and promising results in Phase III trials. Convection-enhanced delivery (CED) of macromolecules has emerged as the leading delivery technique for the treatment of malignant gliomas. A summary of the basic principles of CED and a review of the current human trials of protein targeting agents are provided.
Vandergrift
William A
WA
Division of Neurosurgery, Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina, USA.
Patel
Sunil J
SJ
Nicholas
Joyce S
JS
Varma
Abhay K
AK
D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy / Q000379:methods / Q000639:trends; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D005910:Glioma / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage*; D007260:Infusion Pumps / Q000639:trends; D011868:Radioisotopes / Q000008:administration & dosage*
D000922:Immunotoxins; D011868:Radioisotopes